HK1212356A1 - Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2) 2(loxl2) - Google Patents

Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2) 2(loxl2)

Info

Publication number
HK1212356A1
HK1212356A1 HK15112596.6A HK15112596A HK1212356A1 HK 1212356 A1 HK1212356 A1 HK 1212356A1 HK 15112596 A HK15112596 A HK 15112596A HK 1212356 A1 HK1212356 A1 HK 1212356A1
Authority
HK
Hong Kong
Prior art keywords
loxl2
therapeutic
diagnostic methods
methods related
lysyl oxidase
Prior art date
Application number
HK15112596.6A
Other languages
English (en)
Chinese (zh)
Inventor
．伯恩施泰因
．亞當凱維奇
．史密斯
．萊曼
．簡
李曉明
邵立新
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of HK1212356A1 publication Critical patent/HK1212356A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
    • G01N2333/90605—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4)
    • G01N2333/90633—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general
    • G01N2333/90638—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general with a definite EC number (1.4.3.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7052—Fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HK15112596.6A 2012-10-30 2015-12-22 Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2) 2(loxl2) HK1212356A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261720350P 2012-10-30 2012-10-30
US201261724858P 2012-11-09 2012-11-09
PCT/US2013/067591 WO2014070939A1 (en) 2012-10-30 2013-10-30 Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2)

Publications (1)

Publication Number Publication Date
HK1212356A1 true HK1212356A1 (en) 2016-06-10

Family

ID=49585588

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15112596.6A HK1212356A1 (en) 2012-10-30 2015-12-22 Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2) 2(loxl2)
HK16102662.5A HK1214615A1 (zh) 2012-10-30 2016-03-08 與賴氨醯氧化酶樣蛋白 相關的治療和診斷方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16102662.5A HK1214615A1 (zh) 2012-10-30 2016-03-08 與賴氨醯氧化酶樣蛋白 相關的治療和診斷方法

Country Status (12)

Country Link
US (2) US20140120102A1 (de)
EP (2) EP3348576A1 (de)
JP (2) JP2016500700A (de)
KR (1) KR20150074179A (de)
CN (2) CN107982531A (de)
AU (2) AU2013337908A1 (de)
CA (1) CA2889208A1 (de)
EA (1) EA201590630A1 (de)
HK (2) HK1212356A1 (de)
MX (1) MX2015005448A (de)
SG (2) SG10201703240RA (de)
WO (1) WO2014070939A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2402334T3 (es) 2007-08-02 2013-04-30 Gilead Biologics, Inc Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
WO2015187499A1 (en) * 2014-06-03 2015-12-10 Gilead Sciences, Inc. Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor
US20150361182A1 (en) * 2014-06-11 2015-12-17 Gilead Sciences, Inc. Methods for treating cardiovascular diseases
EP3193855B1 (de) 2014-09-17 2021-05-19 Recurium IP Holdings, LLC Bicyclische verbindungen
WO2016049070A1 (en) * 2014-09-24 2016-03-31 Gilead Sciences, Inc. Methods of treating liver disease
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
KR102594441B1 (ko) 2015-03-06 2023-10-25 파마케아, 인크. 플루오르화된 리실 옥시다아제-유사 2 억제제 및 이의 용도
EP3265445B1 (de) 2015-03-06 2021-05-05 Pharmakea, Inc. Lysyloxidase-like-2-inhibitoren und verwendungen davon
GB201602934D0 (en) * 2016-02-19 2016-04-06 Cancer Res Inst Royal Compounds
CN109983006B (zh) * 2016-09-07 2022-02-25 法玛克亚公司 赖氨酰氧化酶样2抑制剂的结晶形式及其制备方法
CN117180280A (zh) * 2016-09-07 2023-12-08 法玛克亚公司 赖氨酰氧化酶样2抑制剂的用途
JP2019529387A (ja) * 2016-09-07 2019-10-17 ファーマケア，インク． リシルオキシダーゼ様２の化学プローブおよびその使用
GB201704206D0 (en) * 2017-03-16 2017-05-03 Nordic Bioscience As Lysyl oxidase like-2 assay
KR102248165B1 (ko) 2017-12-07 2021-05-06 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
JP7300642B2 (ja) * 2019-06-14 2023-06-30 国立大学法人浜松医科大学 特発性肺線維症の予後予測方法
CN111118142A (zh) * 2020-01-17 2020-05-08 上海市同济医院 血清赖氨酸氧化酶作为肾间质纤维化的分层诊断性生物标志物
CN116064765B (zh) * 2022-08-02 2023-09-05 首都医科大学附属北京友谊医院 检测loxl1基因突变的物质在制备肝纤维化患者分子分型的产品中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
ES2402334T3 (es) 2007-08-02 2013-04-30 Gilead Biologics, Inc Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis
CA2771786A1 (en) * 2009-08-21 2011-02-24 Gilead Biologics, Inc. In vivo screening assays
CA2771630A1 (en) * 2009-08-21 2011-02-24 Victoria Smith Therapeutic methods and compositions
WO2011022670A1 (en) * 2009-08-21 2011-02-24 Arresto Biosciences, Inc In vivo screening assays
MX2012009088A (es) 2010-02-04 2012-12-05 Gilead Biologics Inc Anticuerpos que se enlazan a lisil oxidasa-tipo2 (loxl2) y metodos de uso para los mismos.
US10092552B2 (en) * 2011-01-31 2018-10-09 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
MX2013013905A (es) * 2011-06-01 2014-05-14 Gilead Biologics Inc Ensayo de lisil oxidasa homologo 2 y metodo de uso de la misma.

Also Published As

Publication number Publication date
MX2015005448A (es) 2015-11-06
JP2018083845A (ja) 2018-05-31
CN104755501A (zh) 2015-07-01
KR20150074179A (ko) 2015-07-01
AU2016256820A1 (en) 2016-12-01
US20170327595A1 (en) 2017-11-16
EP2914632A1 (de) 2015-09-09
CN107982531A (zh) 2018-05-04
EA201590630A1 (ru) 2015-10-30
WO2014070939A1 (en) 2014-05-08
SG10201703240RA (en) 2017-06-29
HK1214615A1 (zh) 2016-07-29
EP3348576A1 (de) 2018-07-18
CA2889208A1 (en) 2014-05-08
US20140120102A1 (en) 2014-05-01
AU2013337908A1 (en) 2015-04-30
JP2016500700A (ja) 2016-01-14
SG11201503065PA (en) 2015-05-28

Similar Documents

Publication Publication Date Title
HK1214615A1 (zh) 與賴氨醯氧化酶樣蛋白 相關的治療和診斷方法
IL289759A (en) Formulations for local disinfection and their uses
HK1200872A1 (en) Animal models and therapeutic molecules
HK1209079A1 (en) Catalytic forms and formulations
HK1205964A1 (en) Kit and devices for organ perfusion
SG11201501082RA (en) Diagnostic instrument and methods relating to raman spectroscopy
IL221245A0 (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
EP2534868A4 (de) Verfahren und vorrichtung 'zur durchführung von messungen
EP2534869A4 (de) Verfahren und vorrichtung 'zur durchführung von messungen
EP2651381A4 (de) Verfahren zur verminderung der talgproduktion in der haut
EP2897459A4 (de) Verfahren und systeme zur beurteilung der gesundheit eines organs ex vivo
ZA201308812B (en) Lysyl oxidase-like 2 assay and methods of use thereof
IL236399B1 (en) Polymerizable compositions and methods of use in vivo
ZA201300930B (en) St-246 liquid formulations and methods
ZA201501124B (en) Trans-clomiphene formulations and uses thereof
IL236062A0 (en) In vitro diagnostic device and its uses
EP2609189A4 (de) Verfahren, vorrichtungen und verwendungen in zusammenhang mit biofilmen
HK1206561A1 (en) Skin condition amelioration agent
AU343512S (en) Human model
EP2895186A4 (de) Therapeutische zusammensetzungen und zugehörige verfahren
EP2838508A4 (de) Formulierungen und verfahren zur behandlung von akne und entzündlichen hauterkrankungen
EP2822578A4 (de) Gewebekonstrukte und verwendungen davon
GB201208979D0 (en) Skin and tissue simulant
EP2593925A4 (de) Verfahren und vorrichtung zur glättung von animationen
GB2487444B (en) Improvements in or relating to burial apparatus